181 related articles for article (PubMed ID: 32827429)
1. Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.
Ren N; Tian Z; Sun H; Lu X
Med Sci Monit; 2020 Aug; 26():e924590. PubMed ID: 32827429
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
[TBL] [Abstract][Full Text] [Related]
4. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
5. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
6. Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-Up.
Dong W; Horiuchi K; Tokumitsu H; Sakamoto A; Noguchi E; Ueda Y; Okamoto T
Thyroid; 2019 Jun; 29(6):802-808. PubMed ID: 30931815
[No Abstract] [Full Text] [Related]
7. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.
Xing Y; Luo DY; Long MY; Zeng SL; Li HH
World J Surg Oncol; 2014 Feb; 12():29. PubMed ID: 24485040
[TBL] [Abstract][Full Text] [Related]
8.
Luo J; Zhang B; Cui L; Liu T; Gu Y
Future Oncol; 2019 Apr; 15(12):1303-1311. PubMed ID: 30757917
[No Abstract] [Full Text] [Related]
9. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
Che X; Zhang G; Zhang X; Xue J
Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
[TBL] [Abstract][Full Text] [Related]
10. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
11. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
12. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Chen X; Jin J; Zheng L; Sheng Y; Sun J
J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical significance of STIP1 in papillary thyroid carcinoma.
Yuan MH; Zhou RS; She B; Xu HF; Wang JY; Wei LX
Tumour Biol; 2014 Mar; 35(3):2391-5. PubMed ID: 24163084
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Forkhead box Q1 correlates with poor prognosis in papillary thyroid carcinoma.
Li Y; Wang HQ; Wang AC; Li YX; Ding SS; An XJ; Shi HY
Clin Endocrinol (Oxf); 2019 Feb; 90(2):334-342. PubMed ID: 30378716
[TBL] [Abstract][Full Text] [Related]
16. A-kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients.
Zhang L; Tao H; Ke K; Ma C
J Clin Lab Anal; 2020 Oct; 34(10):e23452. PubMed ID: 32643206
[TBL] [Abstract][Full Text] [Related]
17. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
[TBL] [Abstract][Full Text] [Related]
18. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.
Shen L; Qian C; Cao H; Wang Z; Luo T; Liang C
World J Surg Oncol; 2018 Dec; 16(1):235. PubMed ID: 30558624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
